Nitrogenated heterocyclic compound

Disclosed is a nitrogenated heterocyclic compound represented by general formula (1).  The compound or a salt thereof exhibits a potent antagonistic activity on an EP1 receptor when administered to a human body or an animal.  Therefore, the compound or a salt thereof is useful, for example, as an ac...

Full description

Saved in:
Bibliographic Details
Main Authors ATOBE, MASAKAZU, NAGANUMA, KENJI, MORIMOTO,  AKIFUMI, KOBAYASHI, TERUKI
Format Patent
LanguageEnglish
Published 13.10.2011
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract Disclosed is a nitrogenated heterocyclic compound represented by general formula (1).  The compound or a salt thereof exhibits a potent antagonistic activity on an EP1 receptor when administered to a human body or an animal.  Therefore, the compound or a salt thereof is useful, for example, as an active ingredient for a pharmaceutical agent for preventing and/or treating overactive bladder.  The compound or a salt thereof is also useful as an active ingredient for a pharmaceutical agent for preventing and/or treating a symptom such as frequent urination, urgency of urination or urinary incontinence.
AbstractList Disclosed is a nitrogenated heterocyclic compound represented by general formula (1).  The compound or a salt thereof exhibits a potent antagonistic activity on an EP1 receptor when administered to a human body or an animal.  Therefore, the compound or a salt thereof is useful, for example, as an active ingredient for a pharmaceutical agent for preventing and/or treating overactive bladder.  The compound or a salt thereof is also useful as an active ingredient for a pharmaceutical agent for preventing and/or treating a symptom such as frequent urination, urgency of urination or urinary incontinence.
Author ATOBE, MASAKAZU
KOBAYASHI, TERUKI
NAGANUMA, KENJI
MORIMOTO,  AKIFUMI
Author_xml – fullname: ATOBE, MASAKAZU
– fullname: NAGANUMA, KENJI
– fullname: MORIMOTO,  AKIFUMI
– fullname: KOBAYASHI, TERUKI
BookMark eNrjYmDJy89L5WRQ8sssKcpPT81LLElNUchILUktyk-uTM7JTFZIzs8tyC_NS-FhYE1LzClO5YXS3Awqbq4hzh66qQX58anFBYnJqXmpJfGOoUYGBpZG5kYGxsZOTkbGRCoDALmMKaA
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID AU2009272033BB2
GroupedDBID EVB
ID FETCH-epo_espacenet_AU2009272033BB23
IEDL.DBID EVB
IngestDate Fri Jul 19 13:10:39 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_AU2009272033BB23
Notes Application Number: AU20090272033
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20111013&DB=EPODOC&CC=AU&NR=2009272033B2
ParticipantIDs epo_espacenet_AU2009272033BB2
PublicationCentury 2000
PublicationDate 20111013
PublicationDateYYYYMMDD 2011-10-13
PublicationDate_xml – month: 10
  year: 2011
  text: 20111013
  day: 13
PublicationDecade 2010
PublicationYear 2011
RelatedCompanies ASAHI KASEI PHARMA CORPORATION
RelatedCompanies_xml – name: ASAHI KASEI PHARMA CORPORATION
Score 2.823376
Snippet Disclosed is a nitrogenated heterocyclic compound represented by general formula (1).  The compound or a salt thereof exhibits a potent antagonistic activity...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title Nitrogenated heterocyclic compound
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20111013&DB=EPODOC&locale=&CC=AU&NR=2009272033B2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhR1NS8Mw9DGmqDedil-TIqO3ok0atx6G2C-GsG7IJruNJE3ZQNaxVcR_70todSe9hYR857287wfQEUTkSCUrRxImHU9yxINEMseX5CFXXNDc1b7Dw_RxMPVeZmzWgPfaF8bECf00wRERoiTCe2nw9fpXiBUZ28rtvVhiVfGUTPqRndXiPnxh1I6CfjweRaPQDkPkJO301SgBjMqRBoiw95CQ7mp4iN8C7Zey3v1UkmPYH-N4q_IEGmrVgsOwzr3WgoNhpfLGYgV921O4S5flpsAbx26ZtdCGLIX8krhiS1uG6wRJZ9BJ4kk4cHCy-c_e5s_TnZUFhJ5DE9l-dQGWz3zFsp70sq5OE-aJDLkjzl0ie5QjIXEJ7T-Huvqn_RqOSGXP5tIbaJabD9XGD7YUt-ZcvgEKfH3t
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhR1NS8Mw9DGmOG86FadOi4zeijZp3XoYYr-ounZDOtmttGmKA1nHVhH_vS9h1Z30FhLynffyvh9ALyNZgVQy1xgxmWawFPEgYaZmMXJb8DSjhS58h8PoLpgaTzNz1oD32hdGxgn9lMEREaIYwnsl8fXyV4jlStvK9U02x6ry3o-HrprX4j58YVR17aE3GbtjR3Uc5CTV6EUqAaTKkdqIsHeQyO4LePBebeGXstz-VPwD2J3geIvqEBp80YaWU-dea8NeuFF5Y3EDfesjuI7m1arEG8duufImDFlK9sVwxYqwDBcJko6h53uxE2g4WfKzt-RhurUym9ATaCLbz09BsUyLm_mAGXlfpAkzshy5ozTVCRvQFAmJDnT_HOrsn_YraAVxOEpGj9HzOeyTjW2bTi-gWa0-eBc_2yq7lGf0DR2sgOA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Nitrogenated+heterocyclic+compound&rft.inventor=ATOBE%2C+MASAKAZU&rft.inventor=NAGANUMA%2C+KENJI&rft.inventor=MORIMOTO%2C+%C2%A0AKIFUMI&rft.inventor=KOBAYASHI%2C+TERUKI&rft.date=2011-10-13&rft.externalDBID=B2&rft.externalDocID=AU2009272033BB2